Author: Ken Rubenstein, PhD

Exhibits

Exhibit 3.1 Readout from an Affymetrix DNA microarray experiment
Exhibit 3.2 Affymetrix photolithographic process for DNA microarray manufacturing
Exhibit 3.3 Roche NimbleGen microarray preparation process
Exhibit 3.4 Image of a scan from the NanoString Digital Analyzer showing immobilized and aligned reporter molecules
Exhibit 4.1: Consortia and Joint Programs for Developing Multiplex Biomarkers for Predictive Toxicology
Exhibit 5.1 Selected Deals Involving Multiplex Biomarkers
Exhibit 5.2 Company Category
Exhibit 5.4 Work Function/Pipeline Stage
Exhibit 5.5 Employment of Multiplex Biomarkers in Preclinical Development
Exhibit 5.6 Employment of Multiplex Biomarkers in Phase 0 Clinical Studies
Exhibit 5.7 Employment of Multiplex Biomarkers in Phase I/IIA Clinical Studies
Exhibit 5.8 Employment of Multiplex Biomarkers in Phase IIB/III Clinical Studies
Exhibit 5.9 Employment of Multiplex Biomarkers in Phase IV Clinical Studies
Exhibit 5.10 Use of the Same Multiplex Biomarkers in both Preclinical and Early Clinical Studies
Exhibit 5.11 Would Like to Use Same Multiplex Biomarkers in both Preclinical and Early Clinical Studies
Exhibit 5.12 Organizational Preference to Use Single-Analyte Biomarkers Whenever Possible
Exhibit 5.13 Reasons to Prefer Single Analyte Biomarkers
Exhibit 5.14 Respondent’s Organization Uses Multiplex Biomarkers Preclinically without Formal Validation
Exhibit 5.15 Respondent’s Organization Uses Multiplex Biomarkers in Phase 0 Studies without Formal Validation
Exhibit 5.16 Respondent’s Organization Uses Multiplex Biomarkers in Phase I/IIA Clinical Studies without Formal Validation
Exhibit 5.17 During the Next Three Years, Organization’s Expectation for Multiplex Biomarkers in Preclinical Development
Exhibit 5.18 During the Next Three Years, Organization’s Expectation for Multiplex Biomarkers in Phases I/IIA Clinical Development
Exhibit 5.19 During the Next Three Years, Organization’s Expectation for Multiplex Biomarkers in Phases IIB/III Clinical Development
Exhibit 5.20 Organization has a Drug in Development that Will Have a Companion Diagnostic
Exhibit 5.21 Diagnostic in Development is Single or Multianalyte
Exhibit 5.22 Organization’s View of Companion Diagnostics
Exhibit 5.23 Organization Has a Formal Translational Medicine Group or Function?
Exhibit 5.24 Contribution of Translational Medicine to Respondent’s Organization